Stéphane Bancel, Moderna CEO (Nancy Lane/The Boston Herald via AP Images, Pool)
July 15, 2021 10:34 AM EDT
Bioregnum

With Mod­er­na shares fly­ing at a pan­dem­ic high, the mar­ket cap has now pierced the $100B mark, leapfrog­ging Glax­o­SmithK­line

Back just be­fore the pan­dem­ic hit the world in ear­ly 2020, Mod­er­na’s shares were trad­ing right around $20 a share. To­day, it’s above $250 a …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Lil­ly shuf­fles key ex­ec­u­tive po­si­tions; Mikael Dol­sten takes an­oth­er post-Pfiz­er as­sign­ment

Rev­o­lu­tion’s KRAS drugs ap­pear com­pet­i­tive in sev­er­al lung can­cer set­tings

Corvus' ear­ly-phase atopic der­mati­tis da­ta prompt stock ral­ly

As­traZeneca re­ports Phase 3 win for Imfinzi; Roche to build new man­u­fac­tur­ing site in Chi­na

AI biotech In­sil­i­co Med­i­cine goes for third at­tempt at Hong Kong IPO

sponsored

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

A service from the Financial Times